Skip to main content
Top
Published in: Clinical Research in Cardiology 10/2020

01-10-2020 | Ventricular Tachycardia | Original Paper

Prognostic impact of potassium levels in patients with ventricular tachyarrhythmias

Authors: Tobias Schupp, Thomas Bertsch, Max von Zworowsky, Seung-Hyun Kim, Kathrin Weidner, Jonas Rusnak, Christian Barth, Linda Reiser, Gabriel Taton, Thomas Reichelt, Dominik Ellguth, Niko Engelke, Armin Bollow, Muharrem Akin, Kambis Mashayekhi, Dirk Große Meininghaus, Martin Borggrefe, Ibrahim Akin, Michael Behnes

Published in: Clinical Research in Cardiology | Issue 10/2020

Login to get access

Abstract

Background

The study sought to assess the prognostic impact of potassium levels (K) in patients with ventricular tachyarrhythmias.

Methods

A large retrospective registry was used including all consecutive patients presenting with ventricular tachyarrhythmias on admission from 2002 to 2016. Patients with hypokalemia (i.e., K < 3.3 mmol/L), normokalemia (i.e., K 3.3–4.5 mmol/L), and hyperkalemia (i.e., K > 4.5 mmol/L) were compared applying multi-variable Cox regression models and propensity-score matching for evaluation of the primary endpoint of all-cause mortality at 3 years. Secondary endpoints were early cardiac death at 24 h, in-hospital death, death at 30 days, as well as the composite endpoint of early cardiac death at 24 h, recurrences of ventricular tachyarrhythmias, and appropriate ICD therapies at 3 years.

Results

In 1990 consecutive patients with ventricular tachyarrhythmias, 63% of the patients presented with normokalemia, 30% with hyperkalemia, and 7% with hypokalemia. After propensity matching, both hypokalemic (HR = 1.545; 95% CI 0.970–2.459; p = 0.067) and hyperkalemic patients (HR = 1.371; 95% CI 1.094–1.718; p = 0.006) were associated with the primary endpoint of all-cause mortality at 3 years compared to normokalemic patients. Hyperkalemia was associated with even worse prognosis directly compared to hypokalemia (HR = 1.496; 95% CI 1.002–2.233; p = 0.049). In contrast, potassium measurements were not associated with the composite endpoint at 3 years.

Conclusion

In patients presenting with ventricular tachyarrhythmias, normokalemia was associated with best short- and long-term survival, whereas hyperkalemia and hypokalemia were associated with increased mortality at 30 days and at 3 years.

Graphic abstract

Appendix
Available only for authorised users
Literature
1.
go back to reference Nilsson E, Gasparini A, Arnlov J, Xu H, Henriksson KM, Coresh J et al (2017) Incidence and determinants of hyperkalemia and hypokalemia in a large healthcare system. Int J Cardiol 245:277–284PubMedCrossRef Nilsson E, Gasparini A, Arnlov J, Xu H, Henriksson KM, Coresh J et al (2017) Incidence and determinants of hyperkalemia and hypokalemia in a large healthcare system. Int J Cardiol 245:277–284PubMedCrossRef
2.
go back to reference Collins AJ, Pitt B, Reaven N, Funk S, McGaughey K, Wilson D et al (2017) Association of serum potassium with all-cause mortality in patients with and without heart failure, chronic kidney disease, and/or diabetes. Am J Nephrol 46(3):213–221PubMedPubMedCentralCrossRef Collins AJ, Pitt B, Reaven N, Funk S, McGaughey K, Wilson D et al (2017) Association of serum potassium with all-cause mortality in patients with and without heart failure, chronic kidney disease, and/or diabetes. Am J Nephrol 46(3):213–221PubMedPubMedCentralCrossRef
3.
go back to reference Aldahl M, Jensen AC, Davidsen L, Eriksen MA, Moller Hansen S, Nielsen BJ et al (2017) Associations of serum potassium levels with mortality in chronic heart failure patients. Eur Heart J 38(38):2890–2896PubMedCrossRef Aldahl M, Jensen AC, Davidsen L, Eriksen MA, Moller Hansen S, Nielsen BJ et al (2017) Associations of serum potassium levels with mortality in chronic heart failure patients. Eur Heart J 38(38):2890–2896PubMedCrossRef
5.
go back to reference Schulman M, Narins RG (1990) Hypokalemia and cardiovascular disease. The Am J Cardiol 65(10):4E–9E (discussion 22E-3E)PubMedCrossRef Schulman M, Narins RG (1990) Hypokalemia and cardiovascular disease. The Am J Cardiol 65(10):4E–9E (discussion 22E-3E)PubMedCrossRef
6.
go back to reference Gilligan S, Raphael KL (2017) Hyperkalemia and hypokalemia in CKD: prevalence, risk factors, and clinical outcomes. Adv Chronic Kidney Dis 24(5):315–318PubMedCrossRef Gilligan S, Raphael KL (2017) Hyperkalemia and hypokalemia in CKD: prevalence, risk factors, and clinical outcomes. Adv Chronic Kidney Dis 24(5):315–318PubMedCrossRef
7.
go back to reference Patel RB, Tannenbaum S, Viana-Tejedor A, Guo J, Im K, Morrow DA et al (2017) Serum potassium levels, cardiac arrhythmias, and mortality following non-ST-elevation myocardial infarction or unstable angina: insights from MERLIN-TIMI 36. Eur Heart J Acute Cardiovasc Care 6(1):18–25PubMedCrossRef Patel RB, Tannenbaum S, Viana-Tejedor A, Guo J, Im K, Morrow DA et al (2017) Serum potassium levels, cardiac arrhythmias, and mortality following non-ST-elevation myocardial infarction or unstable angina: insights from MERLIN-TIMI 36. Eur Heart J Acute Cardiovasc Care 6(1):18–25PubMedCrossRef
8.
go back to reference Pun PH, Goldstein BA, Gallis JA, Middleton JP, Svetkey LP (2017) Serum potassium levels and risk of sudden cardiac death among patients with chronic kidney disease and significant coronary artery disease. Kidney Int Rep 2(6):1122–1131PubMedPubMedCentralCrossRef Pun PH, Goldstein BA, Gallis JA, Middleton JP, Svetkey LP (2017) Serum potassium levels and risk of sudden cardiac death among patients with chronic kidney disease and significant coronary artery disease. Kidney Int Rep 2(6):1122–1131PubMedPubMedCentralCrossRef
9.
go back to reference Linde C, Qin L, Bakhai A, Furuland H, Evans M, Ayoubkhani D et al (2019) Serum potassium and clinical outcomes in heart failure patients: results of risk calculations in 21 334 patients in the UK. ESC Heart Fail 6(2):280–290PubMedPubMedCentralCrossRef Linde C, Qin L, Bakhai A, Furuland H, Evans M, Ayoubkhani D et al (2019) Serum potassium and clinical outcomes in heart failure patients: results of risk calculations in 21 334 patients in the UK. ESC Heart Fail 6(2):280–290PubMedPubMedCentralCrossRef
10.
go back to reference Faxen J, Xu H, Evans M, Jernberg T, Szummer K, Carrero JJ (2019) Potassium levels and risk of in-hospital arrhythmias and mortality in patients admitted with suspected acute coronary syndrome. Int J Cardiol 274:52–58PubMedCrossRef Faxen J, Xu H, Evans M, Jernberg T, Szummer K, Carrero JJ (2019) Potassium levels and risk of in-hospital arrhythmias and mortality in patients admitted with suspected acute coronary syndrome. Int J Cardiol 274:52–58PubMedCrossRef
11.
go back to reference Krogager ML, Torp-Pedersen C, Mortensen RN, Kober L, Gislason G, Sogaard P et al (2017) Short-term mortality risk of serum potassium levels in hypertension: a retrospective analysis of nationwide registry data. Eur Heart J 38(2):104–112PubMed Krogager ML, Torp-Pedersen C, Mortensen RN, Kober L, Gislason G, Sogaard P et al (2017) Short-term mortality risk of serum potassium levels in hypertension: a retrospective analysis of nationwide registry data. Eur Heart J 38(2):104–112PubMed
12.
go back to reference Legrand M, Ludes PO, Massy Z, Rossignol P, Parenica J, Park JJ et al (2018) Association between hypo- and hyperkalemia and outcome in acute heart failure patients: the role of medications. Clin Res Cardiol 107(3):214–221PubMedCrossRef Legrand M, Ludes PO, Massy Z, Rossignol P, Parenica J, Park JJ et al (2018) Association between hypo- and hyperkalemia and outcome in acute heart failure patients: the role of medications. Clin Res Cardiol 107(3):214–221PubMedCrossRef
13.
go back to reference de Tymowski C, Atchade E, Montravers P, Provenchere S (2018) Beta-blockers do not protect against cardiac toxicity of hyperkalemia: response to the article by Legrand et al. 'Association between hypo- and hyperkalemia and outcome in acute heart failure patients: the role of medications'. Clin Res Cardiol 107(9):868–869PubMedCrossRef de Tymowski C, Atchade E, Montravers P, Provenchere S (2018) Beta-blockers do not protect against cardiac toxicity of hyperkalemia: response to the article by Legrand et al. 'Association between hypo- and hyperkalemia and outcome in acute heart failure patients: the role of medications'. Clin Res Cardiol 107(9):868–869PubMedCrossRef
14.
go back to reference Krijthe BP, Heeringa J, Kors JA, Hofman A, Franco OH, Witteman JCM et al (2013) Serum potassium levels and the risk of atrial fibrillation: the rotterdam study. Int J Cardiol 168(6):5411–5415PubMedCrossRef Krijthe BP, Heeringa J, Kors JA, Hofman A, Franco OH, Witteman JCM et al (2013) Serum potassium levels and the risk of atrial fibrillation: the rotterdam study. Int J Cardiol 168(6):5411–5415PubMedCrossRef
15.
go back to reference Hoppe LK, Muhlack DC, Koenig W, Carr PR, Brenner H, Schottker B (2018) Association of abnormal serum potassium levels with arrhythmias and cardiovascular mortality: a systematic review and meta-analysis of observational studies. Cardiovasc Drugs Ther 32(2):197–212PubMedCrossRef Hoppe LK, Muhlack DC, Koenig W, Carr PR, Brenner H, Schottker B (2018) Association of abnormal serum potassium levels with arrhythmias and cardiovascular mortality: a systematic review and meta-analysis of observational studies. Cardiovasc Drugs Ther 32(2):197–212PubMedCrossRef
16.
go back to reference Itoh H, Crotti L, Aiba T, Spazzolini C, Denjoy I, Fressart V et al (2016) The genetics underlying acquired long QT syndrome: impact for genetic screening. Eur Heart J 37(18):1456–1464PubMedCrossRef Itoh H, Crotti L, Aiba T, Spazzolini C, Denjoy I, Fressart V et al (2016) The genetics underlying acquired long QT syndrome: impact for genetic screening. Eur Heart J 37(18):1456–1464PubMedCrossRef
17.
go back to reference Kaya A, Keskin M, Tatlisu MA, Kayapinar O (2019) Effect of dynamic potassium change on in-hospital mortality, ventricular arrhythmias, and long-term mortality in STEMI. Angiology 70(1):69–77PubMedCrossRef Kaya A, Keskin M, Tatlisu MA, Kayapinar O (2019) Effect of dynamic potassium change on in-hospital mortality, ventricular arrhythmias, and long-term mortality in STEMI. Angiology 70(1):69–77PubMedCrossRef
18.
go back to reference Pourmoghaddas A, Shemirani H, Garakyaraghi M (2012) Association of serum potassium level with ventricular tachycardia after acute myocardial infarction. ARYA Atheroscler 8(2):79–81PubMedPubMedCentral Pourmoghaddas A, Shemirani H, Garakyaraghi M (2012) Association of serum potassium level with ventricular tachycardia after acute myocardial infarction. ARYA Atheroscler 8(2):79–81PubMedPubMedCentral
19.
go back to reference Priori SG, Blomström-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J et al (2015) 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J 36(41):2793–2867CrossRef Priori SG, Blomström-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J et al (2015) 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J 36(41):2793–2867CrossRef
20.
go back to reference Goyal A, Spertus JA, Gosch K, Venkitachalam L, Jones PG, Van den Berghe G et al (2012) Serum potassium levels and mortality in acute myocardial infarction. JAMA 307(2):157–164PubMedCrossRef Goyal A, Spertus JA, Gosch K, Venkitachalam L, Jones PG, Van den Berghe G et al (2012) Serum potassium levels and mortality in acute myocardial infarction. JAMA 307(2):157–164PubMedCrossRef
22.
23.
go back to reference Austin PC (2011) An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivar Behav Res 46(3):399–424CrossRef Austin PC (2011) An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivar Behav Res 46(3):399–424CrossRef
24.
go back to reference Sugiura A, Kitahara H, Iwahana T, Suzuki N, Okada S, Miyauchi H et al (2019) Association of heart failure duration with clinical prognosis in advanced heart failure. Clin Res Cardiol 109(3):350–357PubMedCrossRef Sugiura A, Kitahara H, Iwahana T, Suzuki N, Okada S, Miyauchi H et al (2019) Association of heart failure duration with clinical prognosis in advanced heart failure. Clin Res Cardiol 109(3):350–357PubMedCrossRef
25.
go back to reference Liu W, Yang J, Hu D, Kang C, Li C, Zhang S et al (2002) KCNQ1 and KCNH2 mutations associated with long QT syndrome in a Chinese population. Hum Mutat 20(6):475–476PubMedPubMedCentralCrossRef Liu W, Yang J, Hu D, Kang C, Li C, Zhang S et al (2002) KCNQ1 and KCNH2 mutations associated with long QT syndrome in a Chinese population. Hum Mutat 20(6):475–476PubMedPubMedCentralCrossRef
26.
go back to reference Yu H, Zhang L, Liu J, Liu Y, Kowey PR, Zhang Y et al (2017) Acquired long QT syndrome in hospitalized patients. Heart Rhythm 14(7):974–978PubMedCrossRef Yu H, Zhang L, Liu J, Liu Y, Kowey PR, Zhang Y et al (2017) Acquired long QT syndrome in hospitalized patients. Heart Rhythm 14(7):974–978PubMedCrossRef
27.
go back to reference Duncker D, Westenfeld R, Konrad T, Pfeffer T, Correia de Freitas CA, Pfister R et al (2017) Risk for life-threatening arrhythmia in newly diagnosed peripartum cardiomyopathy with low ejection fraction a German multi-centre analysis. Clin Res Cardiol 106(8):582–589PubMedPubMedCentralCrossRef Duncker D, Westenfeld R, Konrad T, Pfeffer T, Correia de Freitas CA, Pfister R et al (2017) Risk for life-threatening arrhythmia in newly diagnosed peripartum cardiomyopathy with low ejection fraction a German multi-centre analysis. Clin Res Cardiol 106(8):582–589PubMedPubMedCentralCrossRef
28.
go back to reference Frommeyer G, Reinke F, Andresen D, Kleemann T, Spitzer SG, Jehle J et al (2019) Implantable cardioverter defibrillators in patients with electrical heart disease and hypertrophic cardiomyopathy: data from the German device registry. Clin Res Cardiol. https://doi.org/10.1007/s00392-019-01532-9 Frommeyer G, Reinke F, Andresen D, Kleemann T, Spitzer SG, Jehle J et al (2019) Implantable cardioverter defibrillators in patients with electrical heart disease and hypertrophic cardiomyopathy: data from the German device registry. Clin Res Cardiol. https://​doi.​org/​10.​1007/​s00392-019-01532-9 
29.
go back to reference Kleemann T, Strauss M, Kouraki K, Werner N, Zahn R (2019) Prognostic relevance of new onset arrhythmia and ICD shocks in primary prophylactic ICD patients. Clin Res Cardiol 109(1):89–95PubMedCrossRef Kleemann T, Strauss M, Kouraki K, Werner N, Zahn R (2019) Prognostic relevance of new onset arrhythmia and ICD shocks in primary prophylactic ICD patients. Clin Res Cardiol 109(1):89–95PubMedCrossRef
30.
go back to reference Weidner K, Behnes M, Schupp T, Rusnak J, Reiser L, Taton G et al (2018) Prognostic impact of chronic kidney disease and renal replacement therapy in ventricular tachyarrhythmias and aborted cardiac arrest. Clin Res Cardiol 108(6):669–682PubMedCrossRef Weidner K, Behnes M, Schupp T, Rusnak J, Reiser L, Taton G et al (2018) Prognostic impact of chronic kidney disease and renal replacement therapy in ventricular tachyarrhythmias and aborted cardiac arrest. Clin Res Cardiol 108(6):669–682PubMedCrossRef
31.
go back to reference Schupp T, Akin I, Reiser L, Bollow A, Taton G, Reichelt T et al (2019) Prognostic impact of recurrences of ventricular tachyarrhythmias and appropriate ICD therapies in a high-risk ICD population. Clin Res Cardiol 108(8):878–891PubMedCrossRef Schupp T, Akin I, Reiser L, Bollow A, Taton G, Reichelt T et al (2019) Prognostic impact of recurrences of ventricular tachyarrhythmias and appropriate ICD therapies in a high-risk ICD population. Clin Res Cardiol 108(8):878–891PubMedCrossRef
32.
go back to reference Sedaghat A, Vij V, Streit SR, Schrickel JW, Al-Kassou B, Nelles D et al (2019) Incidence, predictors, and relevance of acute kidney injury in patients undergoing left atrial appendage closure with Amplatzer occluders: a multicentre observational study. Clin Res Cardiol. https://doi.org/10.1007/s00392-019-01524-9 Sedaghat A, Vij V, Streit SR, Schrickel JW, Al-Kassou B, Nelles D et al (2019) Incidence, predictors, and relevance of acute kidney injury in patients undergoing left atrial appendage closure with Amplatzer occluders: a multicentre observational study. Clin Res Cardiol. https://​doi.​org/​10.​1007/​s00392-019-01524-9 
34.
go back to reference AlJaroudi WA, Refaat MM, Habib RH, Al-Shaar L, Singh M, Gutmann R et al (2015) Effect of angiotensin-converting enzyme inhibitors and receptor blockers on appropriate implantable cardiac defibrillator shock in patients with severe systolic heart failure (from the GRADE Multicenter Study). Am J Cardiol 115(7):924–931PubMedPubMedCentralCrossRef AlJaroudi WA, Refaat MM, Habib RH, Al-Shaar L, Singh M, Gutmann R et al (2015) Effect of angiotensin-converting enzyme inhibitors and receptor blockers on appropriate implantable cardiac defibrillator shock in patients with severe systolic heart failure (from the GRADE Multicenter Study). Am J Cardiol 115(7):924–931PubMedPubMedCentralCrossRef
35.
go back to reference Askari AT, Shishehbor MH, Kaminski MA, Riley MJ, Hsu A, Lincoff AM (2009) The association between early ventricular arrhythmias, renin-angiotensin-aldosterone system antagonism, and mortality in patients with ST-segment-elevation myocardial infarction: Insights from Global Use of Strategies to Open coronary arteries (GUSTO) V. Am Heart J 158(2):238–243PubMedCrossRef Askari AT, Shishehbor MH, Kaminski MA, Riley MJ, Hsu A, Lincoff AM (2009) The association between early ventricular arrhythmias, renin-angiotensin-aldosterone system antagonism, and mortality in patients with ST-segment-elevation myocardial infarction: Insights from Global Use of Strategies to Open coronary arteries (GUSTO) V. Am Heart J 158(2):238–243PubMedCrossRef
36.
go back to reference Schupp T, Behnes M, Weiss C, Nienaber C, Lang S, Reiser L et al (2018) Beta-blockers and ACE inhibitors are associated with improved survival secondary to ventricular tachyarrhythmia. Cardiovasc Drugs Ther 32(4):353-363 Schupp T, Behnes M, Weiss C, Nienaber C, Lang S, Reiser L et al (2018) Beta-blockers and ACE inhibitors are associated with improved survival secondary to ventricular tachyarrhythmia. Cardiovasc Drugs Ther 32(4):353-363
37.
go back to reference Schupp T, Behnes M, Weiss C, Nienaber C, Lang S, Reiser L et al (2019) Prognostic impact of angiotensin-converting enzyme inhibitors and receptor blockers on recurrent ventricular tachyarrhythmias and implantable cardioverter-defibrillator therapies. J Cardiovasc Pharmacol 73(5):272–281PubMedCrossRef Schupp T, Behnes M, Weiss C, Nienaber C, Lang S, Reiser L et al (2019) Prognostic impact of angiotensin-converting enzyme inhibitors and receptor blockers on recurrent ventricular tachyarrhythmias and implantable cardioverter-defibrillator therapies. J Cardiovasc Pharmacol 73(5):272–281PubMedCrossRef
38.
go back to reference Schupp T, Behnes M, Ellguth D, Muller J, Reiser L, Bollow A et al (2019) Impact of different pharmacotherapies on long-term outcomes in patients with electrical storm. Pharmacology 103(3–4):179–188PubMedCrossRef Schupp T, Behnes M, Ellguth D, Muller J, Reiser L, Bollow A et al (2019) Impact of different pharmacotherapies on long-term outcomes in patients with electrical storm. Pharmacology 103(3–4):179–188PubMedCrossRef
39.
go back to reference Vardeny O, Claggett B, Anand I, Rossignol P, Desai AS, Zannad F et al (2014) Incidence, predictors, and outcomes related to hypo- and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist. Circ Heart Fail 7(4):573–579PubMedCrossRef Vardeny O, Claggett B, Anand I, Rossignol P, Desai AS, Zannad F et al (2014) Incidence, predictors, and outcomes related to hypo- and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist. Circ Heart Fail 7(4):573–579PubMedCrossRef
40.
go back to reference Rossignol P, Dobre D, McMurray JJ, Swedberg K, Krum H, van Veldhuisen DJ et al (2014) Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). Circ Heart Fail 7(1):51–58PubMedCrossRef Rossignol P, Dobre D, McMurray JJ, Swedberg K, Krum H, van Veldhuisen DJ et al (2014) Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). Circ Heart Fail 7(1):51–58PubMedCrossRef
41.
go back to reference Stienen S, Rossignol P, Barros A, Girerd N, Pitt B, Zannad F et al (2019) Determinants of anti-fibrotic response to mineralocorticoid receptor antagonist therapy: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) and Early Eplerenone Treatment in Patients with Acute ST-elevation Myocardial Infarction without Heart Failure (REMINDER) trials. Clin Res Cardiol 109(2):194–204PubMedCrossRef Stienen S, Rossignol P, Barros A, Girerd N, Pitt B, Zannad F et al (2019) Determinants of anti-fibrotic response to mineralocorticoid receptor antagonist therapy: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) and Early Eplerenone Treatment in Patients with Acute ST-elevation Myocardial Infarction without Heart Failure (REMINDER) trials. Clin Res Cardiol 109(2):194–204PubMedCrossRef
42.
go back to reference Zarraga IG, Dougherty CM, MacMurdy KS, Raitt MH (2012) The effect of spironolactone on ventricular tachyarrhythmias in patients with implantable cardioverter-defibrillators. Circ Arrhythm Electrophysiol 5(4):739–747PubMedCrossRef Zarraga IG, Dougherty CM, MacMurdy KS, Raitt MH (2012) The effect of spironolactone on ventricular tachyarrhythmias in patients with implantable cardioverter-defibrillators. Circ Arrhythm Electrophysiol 5(4):739–747PubMedCrossRef
43.
go back to reference Gupta A, Ladejobi A, Munir MB, Pasupula DK, Bhonsale A, Kancharla K et al (2018) Derivation and validation of a new score to predict long-term survival after sudden cardiac arrest. Pacing Clin Electrophysiol 41(12):1585–1590PubMedCrossRef Gupta A, Ladejobi A, Munir MB, Pasupula DK, Bhonsale A, Kancharla K et al (2018) Derivation and validation of a new score to predict long-term survival after sudden cardiac arrest. Pacing Clin Electrophysiol 41(12):1585–1590PubMedCrossRef
Metadata
Title
Prognostic impact of potassium levels in patients with ventricular tachyarrhythmias
Authors
Tobias Schupp
Thomas Bertsch
Max von Zworowsky
Seung-Hyun Kim
Kathrin Weidner
Jonas Rusnak
Christian Barth
Linda Reiser
Gabriel Taton
Thomas Reichelt
Dominik Ellguth
Niko Engelke
Armin Bollow
Muharrem Akin
Kambis Mashayekhi
Dirk Große Meininghaus
Martin Borggrefe
Ibrahim Akin
Michael Behnes
Publication date
01-10-2020
Publisher
Springer Berlin Heidelberg
Published in
Clinical Research in Cardiology / Issue 10/2020
Print ISSN: 1861-0684
Electronic ISSN: 1861-0692
DOI
https://doi.org/10.1007/s00392-020-01624-x

Other articles of this Issue 10/2020

Clinical Research in Cardiology 10/2020 Go to the issue